VYGR
Voyager's mission is to develop and deliver life-changing therapies to people around the world living with severe neurological diseases.
Voyager Therapeutics, Inc. (VYGR) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Momentum (D).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | B- (3.0) | C+ (2.7) | C (2.3) | D (1.2) | C+ (2.6) | C (2.4) |
| 2026-11-08 | B- (3.0) | C+ (2.6) | C (2.2) | D (1.4) | C+ (2.6) | C (2.4) |
| 2026-11-01 | B- (3.0) | C+ (2.8) | C+ (2.7) | D+ (1.5) | C+ (2.7) | C+ (2.5) |
| 2026-10-25 | B- (3.0) | C+ (2.7) | C+ (2.7) | D (1.4) | C+ (2.6) | C (2.5) |
| 2026-10-18 | B- (3.0) | C+ (2.7) | C+ (2.7) | D+ (1.5) | C+ (2.6) | C+ (2.5) |